173 related articles for article (PubMed ID: 33624224)
1. SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function.
Strazza M; Adam K; Lerrer S; Straube J; Sandigursky S; Ueberheide B; Mor A
Inflammation; 2021 Aug; 44(4):1529-1539. PubMed ID: 33624224
[TBL] [Abstract][Full Text] [Related]
2. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
3. Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor.
Peled M; Tocheva AS; Sandigursky S; Nayak S; Philips EA; Nichols KE; Strazza M; Azoulay-Alfaguter I; Askenazi M; Neel BG; Pelzek AJ; Ueberheide B; Mor A
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):E468-E477. PubMed ID: 29282323
[TBL] [Abstract][Full Text] [Related]
4. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2.
Xu X; Hou B; Fulzele A; Masubuchi T; Zhao Y; Wu Z; Hu Y; Jiang Y; Ma Y; Wang H; Bennett EJ; Fu G; Hui E
J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32437509
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.
Yokosuka T; Takamatsu M; Kobayashi-Imanishi W; Hashimoto-Tane A; Azuma M; Saito T
J Exp Med; 2012 Jun; 209(6):1201-17. PubMed ID: 22641383
[TBL] [Abstract][Full Text] [Related]
6. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
7. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation.
Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U
Front Immunol; 2022; 13():958616. PubMed ID: 35983034
[TBL] [Abstract][Full Text] [Related]
8. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
9. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
Ahmed TA; Adamopoulos C; Karoulia Z; Wu X; Sachidanandam R; Aaronson SA; Poulikakos PI
Cell Rep; 2019 Jan; 26(1):65-78.e5. PubMed ID: 30605687
[TBL] [Abstract][Full Text] [Related]
10. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
11. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
[TBL] [Abstract][Full Text] [Related]
12. Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment.
Quintana E; Schulze CJ; Myers DR; Choy TJ; Mordec K; Wildes D; Shifrin NT; Belwafa A; Koltun ES; Gill AL; Singh M; Kelsey S; Goldsmith MA; Nichols R; Smith JAM
Cancer Res; 2020 Jul; 80(13):2889-2902. PubMed ID: 32350067
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism of SHP2 activation by PD-1 stimulation.
Marasco M; Berteotti A; Weyershaeuser J; Thorausch N; Sikorska J; Krausze J; Brandt HJ; Kirkpatrick J; Rios P; Schamel WW; Köhn M; Carlomagno T
Sci Adv; 2020 Jan; 6(5):eaay4458. PubMed ID: 32064351
[TBL] [Abstract][Full Text] [Related]
14. Novel PROTACs for degradation of SHP2 protein.
Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
[TBL] [Abstract][Full Text] [Related]
15. Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors.
Xu X; Masubuchi T; Cai Q; Zhao Y; Hui E
Elife; 2021 Nov; 10():. PubMed ID: 34734802
[TBL] [Abstract][Full Text] [Related]
16. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy.
Celis-Gutierrez J; Blattmann P; Zhai Y; Jarmuzynski N; Ruminski K; Grégoire C; Ounoughene Y; Fiore F; Aebersold R; Roncagalli R; Gstaiger M; Malissen B
Cell Rep; 2019 Jun; 27(11):3315-3330.e7. PubMed ID: 31189114
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive review of SHP2 and its role in cancer.
Asmamaw MD; Shi XJ; Zhang LR; Liu HM
Cell Oncol (Dordr); 2022 Oct; 45(5):729-753. PubMed ID: 36066752
[TBL] [Abstract][Full Text] [Related]
19. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
